A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 20-2471
More information available at ClinicalTrials.gov: NCT04557735
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers